相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。BRAF Inhibitors: Molecular Targeting and Immunomodulatory Actions
Ilaria Proietti et al.
CANCERS (2020)
Tolerance and Efficacy of BRAF Plus MEK Inhibition in Patients With Melanoma Who Previously Have Received Programmed Cell Death Protein 1-Based Therapy
Karim R. Saab et al.
CANCER (2019)
Possible immune adverse events as predictors of durable response to BRAF inhibitors in patients with BRAF V600-mutant metastatic melanoma
Guy Ben-Betzalel et al.
EUROPEAN JOURNAL OF CANCER (2018)
Immunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapy
Marvin Kuske et al.
PHARMACOLOGICAL RESEARCH (2018)
Acute encephalopathy with combination dabrafenib/trametinib therapy
Jalyn Cooper et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2017)
Acute polyneuropathy in a metastatic melanoma patient treated with vemurafenib and cobimetinib
Annette Compter et al.
NEUROLOGY-CLINICAL PRACTICE (2017)
Immune-Based Antitumor Effects of BRAF Inhibitors Rely on Signaling by CD40L and IFNγ
Ping-Chih Ho et al.
CANCER RESEARCH (2014)
BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma
Dennie T. Frederick et al.
CLINICAL CANCER RESEARCH (2013)
Severe Cutaneous and Neurologic Toxicity in Melanoma Patients during Vemurafenib Administration Following Anti-PD-1 Therapy
Douglas B. Johnson et al.
CANCER IMMUNOLOGY RESEARCH (2013)
分享论文
